Bromazepam: acute benefit-risk assessment in general practice

Curr Med Res Opin. 1984;8(10):683-8. doi: 10.1185/03007998409110117.


A study was carried out in general practice to assess the benefit-risk ratio of a single new drug, bromazepam, prior to marketing. Analysis of data supplied by 393 participating doctors on 3101 patients showed that bromazepam, in a dose range of 3 mg to 9 mg daily in divided doses, was effective as an anxiolytic in 79% of the patients and that the acute risk of treatment was predictable and low. It is concluded that the acute benefit-risk ratio is acceptable with respect to the class of drug and indication for which bromazepam is prescribed.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Anxiety Agents / therapeutic use*
  • Anxiety / drug therapy*
  • Bromazepam / adverse effects
  • Bromazepam / therapeutic use*
  • Child
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Risk


  • Anti-Anxiety Agents
  • Bromazepam